Patent Description:
Lipofuscin is a kind of metabolic wastes produced when various metabolites are digested or processed in intracellular liposomes, and is a yellowish-brown pigmented granule physiologically present in the myocardium. As the amount of lipofuscin accumulates in the cell, the cell function decreases and the aging rate increases.

The heart of a long-lived elderly person is brownish and small because of the increase in lipofuscin pigment, which is called brown atrophy of heart. Such pigmentation may also occur in the liver, which is called brown atrophy of liver. In addition, cases of lipofuscin pigmentation in the heart, liver, and kidneys of cancer patients or patients with long-term wasting diseases such as severe pulmonary tuberculosis have been reported. On the other hand, when the skin is aging, the most prominent phenomenon is pigmentation such as melasma and liver spots, and such pigmentation is a phenomenon in which lipofuscin is accumulated. For this reason, lipofuscin is also called 'liver spot in the body'. Therefore, inhibiting the production and/or accumulation of lipofuscin so that lipofuscin does not accumulate in skin cells is very important in preventing skin aging.

As described above, lipofuscin, which is naturally occurring in the metabolic process of cells, is accumulated in cells in a greater amount when cellular functions decline as well as aging or when repeatedly exposed to external toxins. In addition, the accumulated lipofuscin interferes with the normal function of cells and further accelerates the aging rate. Lipofuscin is found not only in skin cells but also in liver, kidney, heart muscle, retina, adrenal gland, nerve cells and ganglion cells, and is known to accumulate in important body organs and cause various degenerative diseases. For example, when lipofuscin accumulates in the heart muscle, it can worsen the heart muscle and cause myocardial infarction, and when lipofuscin accumulates in the retina or nerve cells, it can cause macular degeneration or Alzheimer's disease. In addition, when it accumulates in organs such as the adrenal gland and liver, pituitary gland, which secrete hormones, abnormalities in the metabolic function of body hormones such as growth hormone and sex hormone may occur.

In one aspect, an object of the present disclosure is to provide a composition comprising a Chryseobacterium camelliae strain, a lysate of the Chryseobacterium camelliae strain, a culture of the Chryseobacterium camelliae strain, or a concentrate obtained by concentrating a culture solution of the Chryseobacterium camelliae strain for use in prevention, amelioration or treatment of a disease caused by the lipofuscin accumulation as defined in the claims.

In another aspect, an object of the present disclosure is to provide a non-therapeutic use of a composition comprising a Chryseobacterium camelliae strain, a lysate of the Chryseobacterium camelliae strain, a culture of the Chryseobacterium camelliae strain, or a concentrate obtained by concentrating a culture solution of the Chryseobacterium camelliae strain for inhibiting lipofuscin accumulation or removing lipofuscin as defined in the claims.

In one aspect, the present disclosure provides a composition comprising a Chryseobacterium camelliae strain, a lysate of the Chryseobacterium camelliae strain, a culture of the Chryseobacterium camelliae strain, or a concentrate obtained by concentrating a culture solution of the Chryseobacterium camelliae strain for the therapeutic and anon-therapeutic use as defined in the claims.

In an exemplary embodiment, the composition may comprise the culture of the Chryseobacterium sp. strain, or the concentrate obtained by concentrating a culture solution of the Chryseobacterium camelliae strain.

In an exemplary embodiment, the strain may be a Chryseobacterium camelliae Dolsongi-HT1 strain having accession number of KCCM11883P.

In an exemplary embodiment, the use may be an use in anti-aging by inhibiting lipofuscin accumulation or removing lipofuscin.

In an exemplary embodiment, the use may be an use in skin whitening by inhibiting lipofuscin accumulation or removing lipofuscin.

In an exemplary embodiment, the use may be an use in prevention, amelioration or treatment of a disease caused by the lipofuscin accumulation, wherein the disease caused by the lipofuscin accumulation is one or more selected from the group consisting of sarcopenia, progeria, Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis (ALS), myocardial infarction, age-related macular degeneration, neuronal ceroid lipofuscinoses (NCL), acromegaly, denervation atrophy and chronic obstructive pulmonary disease (COPD).

In an exemplary embodiment, the non-therapeutic condition is liver spot,.

In an exemplary embodiment, the composition may be a food composition, or a pharmaceutical composition.

In an exemplary embodiment, the composition may comprise <NUM> to <NUM>% by weight of the Chryseobacterium camelliae. strain, the lysate of the Chryseobacterium camelliae. strain, the culture of the Chryseobacterium camelliae. strain, or the concentrate obtained by concentrating a culture solution of the Chryseobacterium camelliae strain, based on a total weight of the composition.

In one aspect, the technology disclosed herein has the effect of providing a composition comprising a Chryseobacterium camelliae strain, a lysate of the Chryseobacterium camelliae strain, a culture of the Chryseobacterium camelliae strain, or a concentrate obtained by concentrating a culture solution of the Chryseobacterium camelliae strain for use in prevention, amelioration or treatment of a disease caused by the lipofuscin accumulation as defined in the claims.

In another aspect, the technology disclosed herein has the effect of providing a non-therapeutic use of a composition comprising a Chryseobacterium camelliae. strain, a lysate of the Chryseobacterium camelliae. strain, a culture of the Chryseobacterium camelliae. strain, or a concentrate obtained by concentrating a culture solution of the Chryseobacterium camelliae strain for inhibiting lipofuscin accumulation or removing lipofuscin as defined in the claims.

In one aspect, the present disclosure provides a composition comprising a Chryseobacterium camelliae strain, a lysate of the Chryseobacterium camelliae strain, a culture of the Chryseobacterium camelliae strain, or a concentrate obtained by concentrating a culture solution of the Chryseobacterium camelliae strain for use in the prevention, amelioration or treatment of a disease caused by lipofuscin accumulation as defined in the claims.

The 'lysate' refers to a product obtained by crushing a microorganism itself by chemical or physical force.

The 'culture' refers to some or all substances contained in a medium in which the microorganisms are cultured, regardless of the form of the culture. For example, the culture may include metabolites or secretions resulting from microbial culture. In addition, the microorganism itself may be included in the culture.

In an exemplary embodiment, the culture is a culture solution itself obtained by culturing the microorganism according to the present disclosure in a suitable liquid medium, a filtered solution (filtrate or centrifuged supernatant) obtained by filtering or centrifuging the culture solution to remove microorganisms, a lysate obtained by sonicating the culture solution or treating the culture solution with a lysozyme, or a concentrated powder obtained by concentrating and freeze-drying the culture solution.

In an exemplary embodiment, the culture may be a culture solution.

In an exemplary embodiment, the culture may be a culture solution obtained by culturing the strain in a liquid medium and then removing the strain.

In an exemplary embodiment, the culture may be a concentrate obtained by concentrating the culture solution.

In an exemplary embodiment, the composition comprising the Chryseobacterium camelliae strain, the lysate of the Chryseobacterium camelliae strain, the culture of the Chryseobacterium camelliae strain, or a concentrate obtained by concentrating a culture solution of the Chryseobacterium camelliae strain may be a composition comprising the culture of the Chryseobacterium camelliae strain or the concentrate obtained by concentrating a culture solution of the Chryseobacterium camelliae strain.

In an exemplary embodiment, the composition comprising the Chryseobacterium camelliae strain, the lysate of the Chryseobacterium camelliae. strain, the culture of the Chryseobacterium camelliae strain, or the concentrate obtained by concentrating a culture solution of the Chryseobacterium camelliae strain may be a composition comprising the culture of the Chryseobacterium camelliae strain.

In an exemplary embodiment, the Chryseobacterium camellia Dolsongi-HT1 strain may have the partial <NUM> rDNA sequence of SEQ ID NO: <NUM>.

In an exemplary embodiment, the composition may be an anti-aging composition.

As used herein, the term 'anti-aging use' refers to the use of preventing, delaying and/or ameliorating the aging phenomenon caused by internal factors including genetic factors and external factors including ultraviolet rays. The composition provides an effect by reducing the level of cellular senescence.

In an exemplary embodiment, the composition may be a whitening composition.

In an exemplary embodiment, the composition comprising the Chryseobacterium camelliae strain, the lysate of the Chryseobacterium camelliae. strain, the culture of the Chryseobacterium camelliae. strain, or the concentrate obtained by concentrating a culture solution of the Chryseobacterium camelliae strain may be one for preventing, ameliorating or treating the disease caused by lipofuscin accumulation, wherein
the disease caused by the lipofuscin accumulation is one or more selected from the group consisting of sarcopenia, progeria, Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis (ALS), myocardial infarction, age-related macular degeneration, neuronal ceroid lipofuscinoses (NCL), acromegaly, denervation atrophy and chronic obstructive pulmonary disease (COPD).

In an exemplary embodiment, the non-therapeutic condition is skin hyperpigmentation, wherein the skin hyperpigmentation is liver spots.

In an exemplary embodiment, the composition comprising the Chryseobacterium camelliae strain, the lysate of the Chryseobacterium camelliae strain, the culture of the Chryseobacterium camelliae strain, or the concentrate obtained by concentrating a culture solution of the Chryseobacterium camelliae strain can inhibit skin hyperpigmentation, wherein the skin hyperpigmentation is liver spots to act on whitening and/or skin tone improvement.

In an exemplary embodiment, the composition comprising the Chryseobacterium camelliae strain, the lysate of the Chryseobacterium camelliae strain, the culture of the Chryseobacterium camelliae strain, or theconcentrate obtained by concentrating a culture solution of the Chryseobacterium camelliae strain may be a food composition or a pharmaceutical composition.

In an exemplary embodiment, the composition comprising the Chryseobacterium camelliae strain, the lysate of the Chryseobacterium camelliae strain, the culture of the Chryseobacterium camelliae strain, or the concentrate obtained by concentrating a culture solution of the Chryseobacterium camelliae strain may be administered or applied to a subject in the form of a cosmetic composition, a food composition or a pharmaceutical composition.

According to an exemplary embodiment, the composition comprising the Chryseobacterium camelliae strain, the lysate of the Chryseobacterium camelliae strain, the culture of the Chryseobacterium camelliae strain, or the concentrate of the culture solution of the Chryseobacterium camelliae strain may be a cosmetic composition.

The cosmetic composition may further include functional additives and components included in general cosmetic compositions. The functional additive may include a component selected from the group consisting of water-soluble vitamins, oil-soluble vitamins, high-molecular peptides, high-molecular polysaccharides, sphingolipids, and seaweed extract. As other ingredients included, there may be oil and fat ingredients, moisturizers, emollients, surfactants, organic and inorganic pigments, organic powders, UV absorbers, preservatives, fungicides, antioxidants, plant extracts, pH regulators, alcohols, pigments, fragrances, blood circulation accelerators, cooling agents, anti-perspiration agents, purified water, etc..

The formulation of the cosmetic composition may be appropriately selected according to the purpose. For example, the cosmetic composition may be prepared in any one or more formulations selected from the group consisting of skin lotion, skin softener, skin toner, astringent, lotion, milk lotion, moisture lotion, nourishing lotion, massage cream, nourishing cream, moisture cream, hand cream, foundation, essence, nourishing essence, pack, soap, cleansing foam, cleansing lotion, cleansing cream, body lotion and body cleanser.

When the formulation of the composition is a paste, cream or gel, animal fiber, vegetable fiber, wax, paraffin, starch, tracanth, cellulose derivative, polyethylene glycol, silicone, bentonite, silica, talc, zinc oxide and the like may be used as a carrier component.

When the formulation of the composition is a powder or a spray, lactose, talc, silica, aluminum hydroxide, calcium silicate or polyamide powder may be used as a carrier component, and in particular, when the formulation of the composition is a spray, additional chlorofluorohydrocarbon, propane/butane or dimethyl ether may be additionally included as propellants.

When the formulation of the composition is a solution or emulsion, a solvent, solvating agent or emulsifying agent is used as a carrier component. For example, water, ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, <NUM>,<NUM>-butylglycol oil, glycerol fatty esters, polyethylene glycol or fatty acid esters of sorbitan may be used.

When the formulation of the composition is a suspension, a liquid diluent such as water, ethanol or propylene glycol, a suspending agent such as ethoxylated isostearyl alcohol, polyoxyethylene sorbitol ester and polyoxyethylene sorbitan ester, microcrystalline cellulose, aluminum metahydroxide, bentonite, agar, tracanth and the like may be used as a carrier component.

When the formulation of the composition is surfactant-containing cleansing, aliphatic alcohol sulfate, aliphatic alcohol ether sulfate, sulfosuccinic acid monoester, isethionate, imidazolinium derivative, methyl taurate, sarcosinate, fatty acid amide ether sulfate, alkylamidobetaine, aliphatic alcohol, fatty acid glyceride, fatty acid diethanolamide, vegetable oil, linolin derivative or ethoxylated glycerol fatty acid ester and the like may be used as carrier components.

According to an exemplary embodiment, the composition comprising the Chryseobacterium camelliae strain, the lysate of the Chryseobacterium camelliae strain, the culture of the Chryseobacterium camelliae strain, or the concentrate of the culture solution of the Chryseobacterium camelliae strain may be a food composition.

The food composition may be in a liquid or solid form. For example, the food composition may include various foods, beverages, gum, tea, vitamin complexes, health supplements, etc., and may be used in the form of powder, granule, tablet, capsule or beverage. Each formulation of the food composition can be appropriately selected and formulated by those skilled in the art without difficulty depending on the formulation or purpose of use of ingredients commonly used in the field, and when applied simultaneously with other raw materials, a synergistic effect may occur.

The liquid formulation may include various flavoring agents or natural carbohydrates as additional ingredients like a conventional beverage. Examples of the natural carbohydrate include monosaccharides, disaccharides such as glucose and fructose, polysaccharides such as maltose and sucrose, common sugars such as dextrin and cyclodextrin, and sugar alcohols such as xylitol, sorbitol, and erythritol etc. As the above flavoring agent, natural flavoring agents (taumatin, stevia extract (e.g., rebaudioside A, glycyrrhizin, etc.) and synthetic flavoring agents (e.g., saccharin, aspartame, etc.) can be advantageously used. The proportion of the natural carbohydrate may be generally about <NUM> to <NUM>, in one aspect, about <NUM> to <NUM> per <NUM> of the composition.

In one aspect, the food composition may include various nutrients, vitamins, minerals (electrolytes), flavoring agents such as synthetic flavoring agents and natural flavoring agents, coloring agents and fillers (cheese, chocolate, etc.), pectic acid and a salt thereof, alginic acid and a salt thereof, organic acids, a protective colloidal thickening agent, a pH regulator, a stabilizer, a preservative, glycerin, alcohol, a carbonate used in carbonated beverages, and the like. In another aspect, it may include pulp for the production of natural fruit juices and vegetable beverages. The above components may be used independently or in combination. The proportion of the additive may vary, but is generally selected from <NUM> to about <NUM> parts by weight based on <NUM> parts by weight of the composition.

According to an exemplary embodiment, the composition comprising the Chryseobacterium camelliae strain, the lysate of the Chryseobacterium camelliae strain, the culture of the Chryseobacterium camelliae strain, or the concentrate obtained by concentrating a culture solution of the Chryseobacterium camelliae strain may be a pharmaceutical composition.

The pharmaceutical composition may further include pharmaceutical adjuvants such as preservatives, stabilizers, wetting agents or emulsification accelerators, salts and/or buffers for regulating osmotic pressure, and other therapeutically useful substances, and the pharmaceutical composition can be formulated in various oral or parenteral administration agents according to a conventional method.

The oral administration agents may include, for example, tablets, pills, hard and soft capsules, solutions, suspensions, emulsifiers, syrups, dusts, powders, fine granules, granules, pellets, etc., and these formulations may include surfactants, diluents (e.g., lactose, dextrose, sucrose, mannitol, sorbitol, cellulose and glycine), lubricants (e.g., silica, talc, stearic acid and its magnesium or calcium salts and polyethylene glycol). Tablets may also include binders such as magnesium aluminum silicate, starch paste, gelatin, tragacanth, methylcellulose, sodium carboxymethylcellulose and polyvinylpyrrolidine, optionally pharmaceutical additives such as disintegrants like starch, agar, alginic acid or its sodium salt, absorbents, colorants, flavoring agents, and sweetening agents. The tablet may be prepared by a conventional mixing, granulating or coating method.

In addition, the parenteral administration form may be a transdermal administration, for example, injections, drops, ointments, lotions, gels, creams, sprays, suspensions, emulsions, patches, etc..

The dosage of the active ingredient is determined within the level of those of ordinary skill in the art, and the daily dosage of the drug varies depending on various factors such as the progress of a subject to be administered, onset time, age, health status, complications, etc. On the basis of an adult, <NUM>µg/kg to <NUM>/kg of the composition in one aspect, and <NUM>µg/kg to <NUM>/kg in another aspect may be administered in divided doses <NUM> to <NUM> times a day.

The pharmaceutical composition may be an external preparation for the skin, and the external preparation for skin is a generic term that may include anything applied outside the skin, and various formulations of pharmaceuticals may be included here.

In an exemplary embodiment, the composition may comprise <NUM> to <NUM>% by weight of the Chryseobacterium camelliae strain, the lysate of the Chryseobacterium camelliae strain, the culture of the Chryseobacterium camelliae strain or the concentrate of the culture solution of the Chryseobacterium camelliae strain based on the total weight of the composition.

In another exemplary embodiment, the composition may comprise <NUM> % by weight or more, <NUM> % by weight or more, <NUM> % by weight or more, or <NUM> % by weight or more, or <NUM> % by weight or less, <NUM> % by weight or less, <NUM> % by weight or less, <NUM> % by weight or less, <NUM> % by weight or less, <NUM> % by weight or less, <NUM> % by weight or less, or <NUM> % by weight or less of the Chryseobacterium camelliae strain, the lysate of the Chryseobacterium camelliae strain, the culture of the Chryseobacterium camelliae strain, or the concentrate obtained by concentrating a culture solution of the Chryseobacterium camelliae strain, based on the total weight of the composition.

For example, the composition may comprise <NUM> to <NUM> % by weight, <NUM> to <NUM> % by weight, <NUM> to <NUM> % by weight, <NUM> to <NUM> % by weight, <NUM> to <NUM> % by weight, <NUM> to <NUM> % by weight, <NUM> to <NUM> % by weight, <NUM> to <NUM>% by weight of the Chryseobacterium camelliae strain, the lysate of the Chryseobacterium camelliae strain, the culture of the Chryseobacterium camelliae strain, or the a concentrate obtained by concentrating a culture solution of the Chryseobacterium camelliae strain, based on the total weight of the composition.

Hereinafter, the present disclosure will be described in more detail with examples. These examples are only for illustrating the present disclosure.

In this example, using the Chryseobacterium Camellia strain as the Chryseobacterium sp. strain, the culture of the Chryseobacterium sp. strain was prepared as follows. As the Chryseobacterium Camellia strain, the Chryseobacterium Camellia Dolsongi-HT1 strain with accession number KCCM11883P was used. The strain can be obtained according to the following separation and identification method as described in <CIT>.

In order to select the microorganisms having plant-derived keratin-decomposing activity, a liquid minimal medium using keratin as a carbon and nitrogen source (M9 medium containing <NUM>% soluble keratin: CaCl<NUM> <NUM>/L, Na<NUM>HPO<NUM> <NUM>/L, KH<NUM>PO<NUM> <NUM>/L, NaCl <NUM>/L, MgSO<NUM> <NUM>/L) was used to incubate microorganisms at <NUM> or <NUM>.

The method for selecting microorganisms using the minimal medium is a method of selecting a target microorganism according to the growth rate of the microorganism. Since microorganisms with low keratinase activity are spontaneously removed in a culturing step, active microorganisms containing highly active enzymes can be selected. It means that microorganisms capable of growing in the minimal medium have keratinase activity.

Accordingly, the microorganisms having keratin-degrading activity were isolated from green tea from Dolsongi tea plantation in Jeju Island, Korea in a limited medium.

In order to identify the isolated microorganisms having keratinase activity, a DNA sequence encoding a partial <NUM> ribosomal RNA sequence of the microorganisms was analyzed to determine the species and genus name.

After the microorganisms were cultured in a liquid medium, genomic DNA was extracted from the microorganisms, and amplified by a polymerase chain reaction (PCR) using 27F (<NUM>'-AGAGTTTGATCMTGGCTCAG-<NUM>', SEQ ID NO: <NUM>)/1492R (<NUM>'-TACGGYTACCTTGTTACGACTT-<NUM>', SEQ ID NO: <NUM>), which is a primer generally used for bacterial identification, and its sequence was analyzed.

As a result of sequencing, it was shown that the sequences had <NUM>% homology with the partial <NUM> rRNA sequence of Chryseobacterium camelliae strain THG C4-<NUM> (KACC <NUM>; Sequence accession number (<NUM> rRNA) JX843771) and <NUM>% homology with the partial <NUM> rRNA sequence of Chryseobacterium taiwanense.

Accordingly, the novel microbial strain isolated and cultured was confirmed to be Chryseobacterium camelliae by the molecular phylogenetic analysis based on the <NUM> rDNA sequence, and this was named Chryseobacterium camelliae Dolsongi-HT1, and this new microbial strain was deposited with accession number KCCM11883P at the Korea Culture Center of Microorganisms (KCCM), a depository institution on September <NUM>, <NUM>. The partial <NUM> rDNA sequence of Chryseobacterium camelliae Dolsongi-HT1 strain of SEQ ID NO: <NUM> is shown in <FIG>.

After seed culture of Chryseobacterium camelliae Dolsongi-HT1 strain derived from green tea for <NUM> hours, <NUM> of the cultured strain was inoculated to <NUM> of the optimal medium (<NUM>% Tryptone/<NUM>% NaCl/<NUM>% Skim milk) and incubated at <NUM> at <NUM> rpm for <NUM> hours. After culturing, a culture solution from which microorganisms were removed was obtained, which was concentrated by ultrafiltration (<NUM> KDa) and washed twice with distilled water. Thereafter, it was filtered using a sterile filter (<NUM>) and then freeze-dried to obtain a concentrated powder of the culture (referred to as HT1).

Normal human dermal fibroblasts (NHDF, Lonza, Switzerland) from a <NUM>-year-old male were cultured in DMEM medium (Dulbecco's modified Eagle's Medium, Gibco <NUM>-<NUM>) containing <NUM>% fetal bovin serum. All cultures were performed in an incubator at <NUM> and <NUM>% CO<NUM> conditions. Cells having a passage number of <NUM> to <NUM> were considered young cells, and it was passaged <NUM> times while subculturing at the cell number ratio of <NUM>:<NUM>.

The dermal fibroblasts cultured in (<NUM>) above were subcultured <NUM> times while treated with the culture of the Chryseobacterium sp. strain obtained in Example <NUM> at a concentration of <NUM> ppm once every <NUM> days.

Thereafter, each cell was washed and placed in a <NUM>-well plate, and the autofluorescence of the lipofuscin pigment was measured using a fluorescence plate reader (Synergy H1 Hybrid Multi-Mode Microplate Reader, BioTeck). The measurement wavelength was measured under the conditions of excitation <NUM>-<NUM> and emission <NUM>-<NUM>. In addition, the subcultured cells were observed under a fluorescent microscope (LSM800, ZEISS).

As a result, as shown in <FIG> and <FIG>, the cells aged <NUM> passages (indicated as P20 in <FIG> and <FIG>) showed a significantly increased amount of lipofuscin compared to cells passaged twice (indicated as P2 in <FIG> and <FIG>). In the case of the experimental group (indicated as <NUM> ppm in <FIG> and <FIG>) treated with the culture of the Chryseobacterium sp. strain together with <NUM> passages, the amount of lipofuscin was reduced by about <NUM>%. Therefore, it was confirmed that the culture of the Chryseobacterium sp. strain have the effect of reducing the amount of lipofuscin that is increased or accumulated due to aging.

Cellular senescence was induced by treating keratinocytes and fibroblasts with doxorubicin, known as a substance that induces aging, respectively, and then the lipofuscin elimination efficacy of the Chryseobacterium sp. strain culture obtained in Example <NUM> was evaluated and confirmed as follows.

Normal human keratinocytes (Lonza, Switzerland) were cultured using KGM™ Gold Keratinocyte Growth Medium BulletKit. In addition, normal human dermal fibroblasts (Lonza, Switzerland) were cultured in DMEM medium (Dulbecco's modified Eagle's Medium, Gibco <NUM>-<NUM>) containing <NUM>% fetal bovin serum. All cultures were performed in an incubator at <NUM> and <NUM>% CO<NUM> conditions. To induce lipofuscin production, <NUM>% confluent keratinocytes and dermal fibroblasts in <NUM>×<NUM> cells/<NUM> well were treated with <NUM> ng/ml of insulin-like growth factor-<NUM> (IGF1) and <NUM> doxorubicin, respectively, once every two days and cultured for <NUM> days. Then, the lipofuscin-produced cells were treated with the culture of the Chryseobacterium sp. strain obtained in Example <NUM> at various concentrations of <NUM> ppm, <NUM> ppm, <NUM> ppm and <NUM> ppm for <NUM> days. After fixing the cells in <NUM>% formalin solution for <NUM> minutes, the fluorescence density was measured using a fluorescent microscope (LSM800, ZEISS), and the results are shown in <FIG> and <FIG>. The measurement wavelength was measured under the conditions of excitation <NUM> and emission <NUM>.

As a result, when the keratinocytes were treated with IGF1 and doxorubicin, about <NUM>% or more of lipofuscin was produced compared to untreated cells. In the case of the experimental group treated with the culture of Chryseobacterium sp. strain after lipofuscin production, lipofuscin was removed in a concentration-dependent manner. In addition, when the fibroblasts were treated with IGF1 and doxorubicin, about <NUM>% or more of lipofuscin was produced compared to untreated cells. In the case of the experimental group treated with the culture of Chryseobacterium sp. strain after lipofuscin production, lipofuscin was removed in a concentration-dependent manner. Therefore, it was confirmed that the culture of the Chryseobacterium sp. strain have the effect of removing lipofuscin produced due to aging.

Formulation examples of the composition according to one aspect of the present disclosure are described below, but other various formulations may also be applied, which is merely to illustrate the present disclosure.

A softening lotion was prepared according to a conventional manufacturing method by mixing <NUM>% by weight of the culture of the Chryseobacterium sp. strain of Example <NUM>, <NUM>% by weight of glycerin, <NUM>% by weight of butylene glycol, <NUM>% by weight of propylene glycol, <NUM>% by weight of carboxyvinyl polymer, <NUM>% by weight of ethanol, <NUM>% by weight of triethanolamine, a trace amount of preservative, a trace amount of colorant, a trace amount of fragrance, and a balance of purified water.

A nutrient lotion was prepared according to a conventional manufacturing method by mixing <NUM>% by weight of the culture of the Chryseobacterium sp. strain of Example <NUM>, <NUM>% by weight of beeswax, <NUM>% by weight of polysorbate <NUM>, <NUM>% by weight of sorbitan sesquioleate, <NUM>% by weight of liquid paraffin, <NUM>% by weight of squalane, <NUM>% by weight of caprylic/capric triglyceride, <NUM>% by weight of glycerin, <NUM>% by weight of butylene glycol, <NUM>% by weight of propylene glycol, <NUM>% by weight of carboxyvinyl polymer, <NUM>% by weight of triethanolamine, a trace amount of preservative, a trace amount of colorant, a trace amount of fragrance and a balance of purified water.

A nutritional cream was prepared according to a conventional manufacturing method by mixing <NUM>% by weight of the culture of the Chryseobacterium sp. strain of Example <NUM>, <NUM>% by weight of beeswax, <NUM>% by weight of polysorbate <NUM>, <NUM>% by weight of sorbitan sesquioleate, <NUM>% by weight of liquid paraffin, <NUM>% by weight of squalane, <NUM>% by weight of caprylic/capric triglyceride, <NUM>% by weight of glycerin, <NUM>% by weight of butylene glycol, <NUM>% by weight of propylene glycol, <NUM>% by weight of triethanolamine, a trace amount of preservative, a trace amount of colorant, a trace amount of fragrance and a balance of purified water.

A pack was prepared according to a conventional manufacturing method by mixing <NUM>% by weight of the culture of the Chryseobacterium sp. strain of Example <NUM>, <NUM>% by weight of polyvinyl alcohol, <NUM>% by weight of sodium carboxymethylcellulose, <NUM>% by weight of allantoin, <NUM>% by weight of ethanol, <NUM>% by weight of nonylphenyl ether, a trace amount of preservative, a trace amount of colorant, a trace amount of fragrance, and a balance of purified water.

According to the composition shown in Table <NUM> below, a drug for topical administration (patch agent) was prepared in a conventional manner.

A powder was prepared by mixing <NUM> of the culture of the Chryseobacterium sp. strain of Example <NUM> and <NUM> of lactose, and then filling the mixture in an airtight bag.

A tablet was prepared by mixing <NUM> of the culture of the Chryseobacterium sp. strain of Example <NUM>, <NUM> of corn starch, <NUM> of lactose, and <NUM> of magnesium stearate, and tableting the mixture according to a conventional manufacturing method.

A capsule was manufactured by mixing <NUM> of the culture of the Chryseobacterium sp. strain of Example <NUM>, <NUM> of corn starch, <NUM> of lactose, and <NUM> of magnesium stearate, and filling the mixture in a gelatin capsule according to a conventional manufacturing method.

A pill was prepared by mixing the culture of the Chryseobacterium sp. strain of Example <NUM>, <NUM> of lactose, <NUM> of glycerin, and <NUM> of xylitol, and processing the mixture so as to be <NUM> per pill according to a conventional manufacturing method.

Granules were prepared by mixing <NUM> of the culture of the Chryseobacterium sp. strain of Example <NUM>, <NUM> of soybean extract, <NUM> of glucose, and <NUM> of starch, adding <NUM> of <NUM>% ethanol to the mixture to dry the mixture at <NUM>, and filling the mixture in a bag.

<NUM> of the culture of the Chryseobacterium sp. strain of Example <NUM>, <NUM> of glucose, <NUM> of citric acid, and <NUM> of liquid oligosaccharide were mixed, <NUM> of purified water was added to the mixture, and <NUM> of the mixture was filled into each bottle. After filling the bottle, it was sterilized at <NUM> for <NUM> to <NUM> seconds to prepare drinks.

Claim 1:
A composition comprising a Chryseobacterium camelliae strain, a lysate of the Chryseobacterium camelliae strain, a culture of the Chryseobacterium camelliae strain, or a concentrate obtained by concentrating a culture solution of the Chryseobacterium camelliae strain for use in prevention, amelioration or treatment of a disease caused by the lipofuscin accumulation, by inhibiting lipofuscin accumulation or removing lipofuscin,
wherein the disease caused by the lipofuscin accumulation is one or more diseases among sarcopenia, progeria, Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis (ALS), myocardial infarction, age-related macular degeneration, neuronal ceroid lipofuscinoses (NCL), acromegaly, denervation atrophy and chronic obstructive pulmonary disease (COPD).